An ACLU brief bolsters the state's case, arguing that people reasonably expect information about the medications they take will be kept confidential.
Philadelphia's innovative treatment program for incarcerated opioid users is failing. Is it because doctors don't want to treat opioid addicts?
Cannabidiol is caught between two worlds.
The number of past-month users was up last year from 2016, but it was still lower than in several previous years.
The FDA approved Epidiolex in June, and today the DEA made it a Schedule V drug, the least restrictive classification for controlled substances.
Does anyone actually call weed "shoe"?
Two years after accepting applications, the DEA has yet to grant licenses to growers.
The attorney general claims that approving new producers of cannabis might violate anti-drug treaties.
The Feds Are Willing to Let More Medical Workers Treat Opioid Addicts. Now the States Need to Step Up and Allow It.
It's time we unleashed non-physicians to help opioid addicts.
"DEA's use of proceeds acquired through civil asset forfeiture to expand marijuana enforcement makes the already unacceptable practice even worse."
"This use of secret evidence may be occurring regularly in cases throughout the country."
Search warrant lists probable cause for distribution and possession with intent to distribute a controlled substance and health care fraud.
Gottlieb isn't a perfect harm reduction advocate, but he's a hell of a lot better than the D.C. status quo.
Do the pain relief benefits of prescription opioids outweigh their addiction risks?
Seize the drugs. Sell the drugs. Arrest the buyers. Repeat.
Acting DEA Administrator Chuck Rosenberg reportedly resigned in part over the Justice Department's obstruction of marijuana research.
"I take the Hippocratic oath seriously that my job is to relieve pain and suffering," says Dr. Forest Tennant, a California pain specialist who patients from across the nation are flocking to see.
A new government watchdog report finds the DEA grabs cash just for the sake of grabbing cash, raising civil liberties concerns.
Doctors using DEA-approved marijuana find it is useless for research purposes.
The DEA's backtracking underlines the arbitrariness of the government's pharmacological taboos.
After backlash, they've extended the comment period and called for FDA input.
One informant lied in court and still worked for the DEA, pocketing over $469,000 in a five-year span.
After meeting with the DEA administrator, Rep. Mark Pocan says the agency may allow for more public comment on whether to make Kratom a Schedule I drug.
"Our goal is to make sure this is available," a spokesman says.
How much do politicians really care about veterans' health?
As far as the DEA is concerned, the leaf has no legitimate uses.
With NIDA as the only legal source of cannabis for research, meeting FDA requirements was impossible.
The Controlled Substances Act established arbitrary rules that make it impossible to properly categorize many drugs.
The agency won't reclassify cannabis but will make it easier for scientists to get the kind they need.
Raids on facilities and attempts at asset forfeiture.
The agency always drags its feet before saying no, saying yes would require an embarrassing reversal, and the president has passed the buck to Congress.
The president prefers to pretend that rescheduling requires congressional action.
In the government's new war on opiates, physicians and their patients find themselves caught in the crossfire.
But the case, which hinged on the DEA's broad statutory discretion, does not say much about the SCOTUS nominee's drug policy views.